Now a technological breakthrough, outlined in a paper published by the journal Nature Chemical Biology, has just been developed that could unlock the floodgates for new drugs originating from fungi. The process involves using genomics and data analytics to capture fungal DNA and then identify promising new chemical molecules that could become the basis of a range of new drugs.
“New chemical matter from the fungal world can now be extracted,” senior author Neil Kelleher, a chemical biologist at Northwestern University, told Seeker. “So it’s like mining for gold, but instead of small labs panning for nuggets, the process can now be industrialized.”
The technology developed by Kelleher, lead author Kenneth Clevenger, and their colleagues consists of a three-step system. First, genomics and molecular biology are used to identify and capture broad portions of fungal DNA known as gene clusters. Next, the gene clusters are placed into a model fungus: Aspergillus nidulans.
Clevenger explained that this fungus “is one of the most studied fungi out there, so we know a lot about it biology and chemistry.” As a result, he continued, scientists can then distinguish with greater ease new molecules from those in the fungus that are already well documented.
The final step is to utilize mass spectrometry and data analytics to analyze the resulting fungal compounds.
The researchers applied the three-step technology to investigate three diverse fungal species, and discovered 17 new compounds from the 56 gene clusters that they screened. Kelleher noted that this is “a great hit rate in the business of natural products discovery.”
The team named one of the new metabolites valactamide A, and it is now the focus of additional study. Co-author Nancy Keller of the University of Wisconsin-Madison said that fungi often produce such metabolites as protectants and weapons from other microbes or environmental stresses.
“Due to these properties,” she said, “many fungal metabolites become very valuable in treating human disease by targeting pathogenic microbes or malfunctioning human enzymes.”
For example, the fungi-sourced lovastatin targets an enzyme — HGM-CoA reductase — found in both humans and fungi. This enzyme is needed to produce cholesterol in humans as well as the fungi version of cholesterol, called ergosterol. When lovastatin interacts with the enzyme in a person, it can lower that individual’s LDL cholesterol (popularly known as the “bad” cholesterol). The drug also has antifungal properties.
“It’s likely that many fungi-sourced compounds with medical potential will be antimicrobial, but based on past history, we can also expect drugs to target the human immune response and high cholesterol, among others,” Clevenger said.
Other tech advances in recent years have led to the realization that good health often has more to do with a well-balanced microbiome than the presence — or absence — of any particular supposed beneficial or detrimental agent.
Read more at Discovery News